By using in vitro and in vivo preclinical models, and an observational study in patients with obesity and T2D, our project aims to:
Objectives
- Discover and dissect the role of dAGEs/RAGE axis in WD-induced MW;
- Unravel genes, pathways and metabolomic signature affected by WD, thus identifying therapeutic targets for sarcobesity;
- Test anti-dAGEs natural compounds as an approach to maintain muscle mass and functionality, and reduce the risk of comorbidities associated to to WD intake;
- Correlate the level of dietary and endogenous AGEs with the severity of sarcopenia;
- Identify dAGEs as potential reliable biomarkers of MW risk in patients with obesity and T2D, with high clinical relevance in prevention and early screening of sarcobesity.
